We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+0.37%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.56B
AUM Growth
-$92.1M
Cap. Flow
-$16.4M
Cap. Flow %
-1.05%
Top 10 Hldgs %
77.78%
Holding
44
New
2
Increased
8
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
RVNC
Revance Therapeutics, Inc.
RVNC
+$19.5M
2
EHTH icon
eHealth
EHTH
+$15.6M
3
SAGE
Sage Therapeutics
SAGE
+$6.86M
4
BIIB icon
Biogen
BIIB
+$6.02M
5
ALKS icon
Alkermes
ALKS
+$4.32M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$17.3M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$16.7M
3
ABMD
Abiomed Inc
ABMD
+$10.4M
4
AZN icon
AstraZeneca
AZN
+$10.1M
5
PBYI icon
Puma Biotechnology
PBYI
+$9.77M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Financials 2.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$13.6B
$196M 12.49%
2,212,950
– –
ABMD
2
DELISTED
Abiomed Inc
ABMD
$186M 11.91%
519,033
-30,787
-6% -$10.4M
INSM icon
3
Insmed
INSM
$29B
$164M 10.49%
6,025,706
+6,600
+0.1% +$189K
UTHR icon
4
United Therapeutics
UTHR
$22.8B
$148M 9.49%
687,206
– –
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$117M 7.47%
10,114,043
– –
STAA icon
6
STAAR Surgical
STAA
$1.26B
$104M 6.65%
1,140,511
– –
BIIB icon
7
Biogen
BIIB
$30.6B
$92.4M 5.9%
385,000
+23,400
+6% +$6.02M
PRTA icon
8
Prothena Corp
PRTA
$469M
$83.3M 5.32%
1,685,282
– –
RVNC
9
DELISTED
Revance Therapeutics, Inc.
RVNC
$71.3M 4.56%
4,369,366
+1,167,500
+36% +$19.5M
ACAD icon
10
Acadia Pharmaceuticals
ACAD
$5.08B
$54.6M 3.49%
2,337,877
– –
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$300M
$44.5M 2.84%
2,834,244
-957,561
-25% -$16.7M
EHTH icon
12
eHealth
EHTH
$40.4M
$41.2M 2.63%
1,615,570
+469,700
+41% +$15.6M
ALGN icon
13
Align Technology
ALGN
$12.6B
$36.4M 2.33%
55,405
– –
KPTI icon
14
Karyopharm Therapeutics
KPTI
$45.3M
$35.2M 2.25%
364,697
+5,827
+2% +$581K
SAGE
15
DELISTED
Sage Therapeutics
SAGE
$33.3M 2.13%
781,730
+163,800
+27% +$6.86M
GRTS
16
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$30.3M 1.94%
2,356,282
– –
GOSS icon
17
Gossamer Bio
GOSS
$87M
$20.1M 1.28%
1,772,950
– –
ALKS icon
18
Alkermes
ALKS
$8.36B
$17.5M 1.12%
754,200
+164,300
+28% +$4.32M
ANAB icon
19
AnaptysBio
ANAB
$1.73B
$15.2M 0.97%
436,592
– –
EPZM
20
DELISTED
Epizyme, Inc
EPZM
$13.7M 0.88%
5,485,213
-1,371,300
-20% -$5.39M
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.84B
$13.1M 0.84%
598,900
+154,000
+35% +$2.85M
KZR
22
DELISTED
Kezar Life Sciences
KZR
$11M 0.7%
65,620
– –
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
$10.8M 0.69%
3,997,826
-486,585
-11% -$1.8M
CYTK icon
24
Cytokinetics
CYTK
$11B
$5.64M 0.36%
123,686
– –
TVTX icon
25
Travere Therapeutics
TVTX
$5.76B
$5.16M 0.33%
166,069
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Palo Alto Investors's Q4 2021 Portfolio in Review

As of Q4 2021, Palo Alto Investors held 44 positions worth $1.56B, down 5.6% from $1.66B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Palo Alto Investors's Q4 2021 filing shows 2 new, 8 increased, 7 reduced and 7 closed positions. Its largest new stake was Novavax: 12,500 shares worth $1.79M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q4 2021 buy was Novavax: 12,500 shares worth $1.79M.
  • Palo Alto Investors added most to Revance Therapeutics, Inc. in Q4 2021, an estimated $19.5M increase.
  • Palo Alto Investors's biggest Q4 2021 reduction was Vanda Pharmaceuticals, cutting an estimated $16.7M.
  • Palo Alto Investors fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $17.3M.
  • Palo Alto Investors's ten largest holdings make up 78% of its $1.56B portfolio in Q4 2021.
  • Palo Alto Investors opened 2 new positions and closed 7 in Q4 2021.
  • Palo Alto Investors's portfolio value fell 5.6% quarter-over-quarter to $1.56B.

Based on Palo Alto Investors's 13F filing for Q4 2021, filed 14 Feb 2022.